Glenmark Life Sciences Share Price

Glenmark Life Sciences Investment Rating

• Master Rating:

• Glenmark Life Sciences has an operating revenue of Rs. 2,088.19 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 27% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 5 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 151 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.